Find Cabozantinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

MARKET PLACE

FDF DossiersDRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1140909-48-3, Cabozantinib malate, Cabozantinib (s)-malate, Cabometyx, Cabozantinib malate (xl184), Xl184
Molecular Formula
C32H30FN3O10
Molecular Weight
635.6  g/mol
InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
FDA UNII
DR7ST46X58

Cabozantinib
Cabozantinib S-malate is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Cabozantinib strongly binds to and inhibits several RTKs, which are often overexpressed in a variety of cancer cell types, including hepatocyte growth factor receptor (MET), RET (rearranged during transfection), vascular endothelial growth factor receptor types 1 (VEGFR-1), 2 (VEGFR-2), and 3 (VEGFR-3), mast/stem cell growth factor (KIT), FMS-like tyrosine kinase 3 (FLT-3), TIE-2 (TEK tyrosine kinase, endothelial), tropomyosin-related kinase B (TRKB) and AXL. This may result in an inhibition of both tumor growth and angiogenesis, and eventually lead to tumor regression.
1 2D Structure

Cabozantinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2S)-2-hydroxybutanedioic acid
2.1.2 InChI
InChI=1S/C28H24FN3O5.C4H6O5/c1-35-24-15-21-22(16-25(24)36-2)30-14-11-23(21)37-20-9-7-19(8-10-20)32-27(34)28(12-13-28)26(33)31-18-5-3-17(29)4-6-18;5-2(4(8)9)1-3(6)7/h3-11,14-16H,12-13H2,1-2H3,(H,31,33)(H,32,34);2,5H,1H2,(H,6,7)(H,8,9)/t;2-/m.0/s1
2.1.3 InChI Key
HFCFMRYTXDINDK-WNQIDUERSA-N
2.1.4 Canonical SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C(C(C(=O)O)O)C(=O)O
2.1.5 Isomeric SMILES
COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F.C([C@@H](C(=O)O)O)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
DR7ST46X58
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bms 907351

2. Bms-907351

3. Bms907351

4. Cabozantinib

5. Cometriq

6. Xl 184

7. Xl-184

8. Xl184 Cpd

2.3.2 Depositor-Supplied Synonyms

1. 1140909-48-3

2. Cabozantinib Malate

3. Cabozantinib (s)-malate

4. Cabometyx

5. Cabozantinib Malate (xl184)

6. Xl184

7. Cabozantinib (s-malate)

8. Cometriq

9. Cabozantinib S-malate [usan]

10. Dr7st46x58

11. Bms907351

12. Chebi:72319

13. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

14. Cabometyx (tn)

15. Cometriq (tn)

16. Cabozantinib Malate (jan)

17. 1-n-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide;(2s)-2-hydroxybutanedioic Acid

18. Cabozantinib S-malate (usan)

19. Cabozantinib Malate [jan]

20. Unii-dr7st46x58

21. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-(4-((6,7-dimethoxy-4-quinolinyl)oxy)phenyl)-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

22. Butanedioic Acid, 2-hydroxy-, (2s)-, Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

23. Xl184 Malate

24. Cabozantinib L-malate

25. Bms907351 Malate

26. Xl184(cabozantinib Malate)

27. Mls006010951

28. Chembl2103868

29. Dtxsid60915949

30. Ex-a2819

31. Mfcd20923480

32. S4001

33. 1140909-48-3 (malate)

34. Akos025401945

35. Cabozantinib S-malate [who-dd]

36. Ccg-270301

37. Cs-0201

38. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluor

39. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

40. Ac-27471

41. As-75255

42. Hy-12044

43. Smr004702755

44. Cabozantinib S-malate [orange Book]

45. Sw218093-2

46. D10095

47. Q27139901

48. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide

49. (2s)-2-hydroxybutanedioic Acid Compd. With N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide (1:1)

50. (2s)-2-hydroxybutanedioic Acid; N'1-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n1-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide

51. 1,1-cyclopropanedicarboxamide, N'-(4-((6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-n-(4- Fluorophenyl)- Mono((2s)-2-hydroxybutanedioate)

52. Cyclopropane-1,1-dicarboxylic Acid [4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amide, (s) Malate Salt

53. N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide Mono((2s)-2-hydroxybutanedioate)

54. N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-n-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (s)-2-hydroxysuccinate

55. N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (2s)-2-hydroxybutanedioate

2.4 Create Date
2008-12-22
3 Chemical and Physical Properties
Molecular Weight 635.6 g/mol
Molecular Formula C32H30FN3O10
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count12
Rotatable Bond Count11
Exact Mass635.19152232 g/mol
Monoisotopic Mass635.19152232 g/mol
Topological Polar Surface Area194 Ų
Heavy Atom Count46
Formal Charge0
Complexity924
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

* Renal Cell Carcinoma (RCC):

Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):

- in treatment-nave adults with intermediate or poor risk,

- in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.

Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.

* Hepatocellular Carcinoma (HCC):

Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EX07


API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636655400,"product":"CABOZANTINIB (TAX INV NO:1905215257, DT","address":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR","city":"HYDERABAD, A.P.","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.60","actualQuantity":"1.6","unit":"KGS","unitRateFc":"14850","totalValueFC":"23499","currency":"USD","unitRateINR":1093750,"date":"12-Nov-2021","totalValueINR":"1750000","totalValueInUsd":"23499","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"5943324","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"8-3-167\/D\/16, KALYAN NAGAR - I,VENGAL RAO NAGAR, HYDERABAD, A.P.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653503400,"product":"CABOZANTINIB (TAX INVOICE NO:1905225050","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"GULF AGENCY COMPANY ","customerCountry":"UNITED ARAB EMIRATES","quantity":"1.60","actualQuantity":"1.6","unit":"KGS","unitRateFc":"14850","totalValueFC":"23574.9","currency":"USD","unitRateINR":1138750,"date":"26-May-2022","totalValueINR":"1822000","totalValueInUsd":"23574.9","indian_port":"HYDERABAD AIR","hs_no":"29337990","bill_no":"1673014","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1681065000,"product":"CABOZANTINIB IH","address":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta","city":"HYDERABAD","supplier":"HETERO DRUGS","supplierCountry":"INDIA","foreign_port":"TAIPEI","customer":"TO THE ORDER OF","customerCountry":"TAIWAN","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"12000","totalValueFC":"11640.7","currency":"USD","unitRateINR":954000,"date":"10-Apr-2023","totalValueINR":"954000","totalValueInUsd":"11640.7","indian_port":"HYDERABAD AIR","hs_no":"29241900","bill_no":"9191918","productDescription":"API","marketType":"REGULATED MARKET","country":"TAIWAN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"HETERO CORPORATE, NO. 7-2-A2, INDUSTRIAL ESTATE,SANATHNAGAR Conta, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683743400,"product":"CABOZANTINIB (S)-MALATE","address":"101, SAPTAGIRI RESIDENCY,1-10-98\/A, CHIKOTI GARDENS, BEGUMPET,","city":"HYDERABAD, AP.","supplier":"ESCIENTIA ADVANCED SCIENCES ","supplierCountry":"INDIA","foreign_port":"SHEREMETYEVO APT\/MOS","customer":"MM FARMACHEM D.O.O","customerCountry":"RUSSIA","quantity":"0.20","actualQuantity":"200","unit":"GMS","unitRateFc":"20.5","totalValueFC":"4032.9","currency":"USD","unitRateINR":1659.23,"date":"11-May-2023","totalValueINR":"331846","totalValueInUsd":"4032.9","indian_port":"Vizag-APIICL SEZ","hs_no":"29334900","bill_no":"4001688","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Vizag-APIICL SEZ","supplierAddress":"101, SAPTAGIRI RESIDENCY,1-10-98\/A, CHIKOTI GARDENS, BEGUMPET,, HYDERABAD, AP.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1688668200,"product":"CABOZANTINIB HCL IH (MICRONIZED)","address":"H.NO. 8-2-337,BESIDE TV9 OFFICE","city":"HYDERABAD ANDHRA PRADESH","supplier":"DR. REDDY\\'S LABORATORIES","supplierCountry":"INDIA","foreign_port":"MONTREAL","customer":"PHARMASCIENCE INC","customerCountry":"CANADA","quantity":"13.00","actualQuantity":"13","unit":"KGS","unitRateFc":"21092","totalValueFC":"272062.1","currency":"USD","unitRateINR":1720050.4615384615,"date":"07-Jul-2023","totalValueINR":"22360656","totalValueInUsd":"272062.1","indian_port":"Reddy r-SEZ\/Srikakulam","hs_no":"29141990","bill_no":"4000404","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Micronized","supplierPort":"Reddy r-SEZ\/Srikakulam","supplierAddress":"H.NO. 8-2-337,BESIDE TV9 OFFICE, HYDERABAD ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1690828200,"product":"CABOZANTINIB (S) MALATE","address":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR","city":"Hyderabad","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"NA","customer":"TO THE ORDER OF","customerCountry":"CHINA","quantity":"4.50","actualQuantity":"4.5","unit":"KGS","unitRateFc":"15955.1","totalValueFC":"70986.5","currency":"USD","unitRateINR":1306724.1459999999,"date":"01-Aug-2023","totalValueINR":"5880258.657","totalValueInUsd":"70986.5","indian_port":"HYDERABAD ICD","hs_no":"29337990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CHINA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD ICD","supplierAddress":"MSN HOUSE PLOT NO. C-24INDUSTRI AL ESTATE SANATH NAGAR, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710095400,"product":"CABOZANTINIB (S)-MALATE","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"MALTA","customer":"PHARMACARE PREMIUM","customerCountry":"MALTA","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"20000","totalValueFC":"5646.8","currency":"USD","unitRateINR":1562956.6666666667,"date":"11-Mar-2024","totalValueINR":"468887","totalValueInUsd":"5646.8","indian_port":"Hyderabad Air","hs_no":"29337990","bill_no":"8222802","productDescription":"API","marketType":"REGULATED MARKET","country":"MALTA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""}]
12-Nov-2021
11-Mar-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Europe

read-more
read-more

01

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 20 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

02

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 40 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

03

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Antic-calc Tablet, Film Coated

Dosage Strength : 60 mg

Packaging : Bottle

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

04

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form :

Dosage Strength :

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

05

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form :

Dosage Strength :

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

06

Ipsen Pharma

France
Arab Health
Not Confirmed
arrow

Ipsen Pharma

France
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cometriq

Dosage Form : Capsule, hard

Dosage Strength : 20 mg

Packaging : Blister

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Norway

blank

07

Arab Health
Not Confirmed
arrow
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 20mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

08

Arab Health
Not Confirmed
arrow
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 40mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

09

Arab Health
Not Confirmed
arrow
arrow
Arab Health
Not Confirmed

Cabozantinib

Brand Name : Cabometyx

Dosage Form : Film-Coated Tablets

Dosage Strength : 60mg

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Switzerland

blank

10

TMC Pharma Services Ltd.,

Country
Arab Health
Not Confirmed
arrow

TMC Pharma Services Ltd.,

Country
arrow
Arab Health
Not Confirmed

kabozantinib S-malate

Brand Name : Cometriq

Dosage Form : HARD CAPSULES

Dosage Strength : 20 MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Sweden

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 20MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

DOSAGE - CAPSULE;ORAL - EQ 80MG BASE

USFDA APPLICATION NUMBER - 203756

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Direct Compression

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Co-Processed Excipients

read-more
read-more

Empty Capsules

read-more
read-more

Coloring Agents

read-more
read-more

Emulsifying Agents

read-more
read-more

Vegetarian Capsules

read-more
read-more

API Stability Enhancers

read-more
read-more

Taste Masking

read-more
read-more

Topical

read-more
read-more

Solubilizers

read-more
read-more

Rheology Modifiers

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Parenteral

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

STOCK RECAP #PipelineProspector

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Cabozantinib S-Malate Manufacturers

A Cabozantinib S-Malate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cabozantinib S-Malate, including repackagers and relabelers. The FDA regulates Cabozantinib S-Malate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cabozantinib S-Malate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Cabozantinib S-Malate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Cabozantinib S-Malate Suppliers

A Cabozantinib S-Malate supplier is an individual or a company that provides Cabozantinib S-Malate active pharmaceutical ingredient (API) or Cabozantinib S-Malate finished formulations upon request. The Cabozantinib S-Malate suppliers may include Cabozantinib S-Malate API manufacturers, exporters, distributors and traders.

click here to find a list of Cabozantinib S-Malate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Cabozantinib S-Malate USDMF

A Cabozantinib S-Malate DMF (Drug Master File) is a document detailing the whole manufacturing process of Cabozantinib S-Malate active pharmaceutical ingredient (API) in detail. Different forms of Cabozantinib S-Malate DMFs exist exist since differing nations have different regulations, such as Cabozantinib S-Malate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Cabozantinib S-Malate DMF submitted to regulatory agencies in the US is known as a USDMF. Cabozantinib S-Malate USDMF includes data on Cabozantinib S-Malate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Cabozantinib S-Malate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Cabozantinib S-Malate suppliers with USDMF on PharmaCompass.

Cabozantinib S-Malate KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Cabozantinib S-Malate Drug Master File in Korea (Cabozantinib S-Malate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Cabozantinib S-Malate. The MFDS reviews the Cabozantinib S-Malate KDMF as part of the drug registration process and uses the information provided in the Cabozantinib S-Malate KDMF to evaluate the safety and efficacy of the drug.

After submitting a Cabozantinib S-Malate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Cabozantinib S-Malate API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Cabozantinib S-Malate suppliers with KDMF on PharmaCompass.

Cabozantinib S-Malate WC

A Cabozantinib S-Malate written confirmation (Cabozantinib S-Malate WC) is an official document issued by a regulatory agency to a Cabozantinib S-Malate manufacturer, verifying that the manufacturing facility of a Cabozantinib S-Malate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Cabozantinib S-Malate APIs or Cabozantinib S-Malate finished pharmaceutical products to another nation, regulatory agencies frequently require a Cabozantinib S-Malate WC (written confirmation) as part of the regulatory process.

click here to find a list of Cabozantinib S-Malate suppliers with Written Confirmation (WC) on PharmaCompass.

Cabozantinib S-Malate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Cabozantinib S-Malate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Cabozantinib S-Malate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Cabozantinib S-Malate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Cabozantinib S-Malate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Cabozantinib S-Malate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Cabozantinib S-Malate suppliers with NDC on PharmaCompass.

Cabozantinib S-Malate GMP

Cabozantinib S-Malate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Cabozantinib S-Malate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cabozantinib S-Malate GMP manufacturer or Cabozantinib S-Malate GMP API supplier for your needs.

Cabozantinib S-Malate CoA

A Cabozantinib S-Malate CoA (Certificate of Analysis) is a formal document that attests to Cabozantinib S-Malate's compliance with Cabozantinib S-Malate specifications and serves as a tool for batch-level quality control.

Cabozantinib S-Malate CoA mostly includes findings from lab analyses of a specific batch. For each Cabozantinib S-Malate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Cabozantinib S-Malate may be tested according to a variety of international standards, such as European Pharmacopoeia (Cabozantinib S-Malate EP), Cabozantinib S-Malate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cabozantinib S-Malate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty